TAR-200, a gemcitabine-releasing system, received FDA priority review for high-risk non-muscle invasive bladder cancer unresponsive to BCG. Phase 2b SunRISe-1 trial data showed an 82.4% complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback